have reported that lauric acid can induce miR-378 expression and increase the sensitivity of BRAF- and KRAS-mutant CRC cells to cetuximab by inhibiting KRAS, BRAF, MEK, ERK1/2 protein expressions through the MAPK signaling pathway (48). Here, KRAS is linked to colorectal carcinoma.